
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow Inc. experienced robust growth, with approximately 48% worldwide volume growth in its FFR-CT segment, resulting in 3Q25 revenues of $46.3 million, a 41% increase year-over-year, outperforming consensus projections. The company's gross margins improved to 76.8%, showcasing strong operational efficiency and profitability, crucial for long-term financial stability. Additionally, management emphasized healthy fundamentals, with increasing adoption of coronary CT angiography and a growing number of accounts, positioning HeartFlow for sustained revenue growth in the mid-20s percentage range for the foreseeable future.
Bears say
HeartFlow Inc. has consistently incurred significant net losses since its inception, with reported losses of $95.7 million for FY23 and $96.4 million for FY24, raising concerns about its ability to achieve profitability in the foreseeable future. The company's projected revenue of $173 million to $173.5 million for 2025, which implies flat revenue growth in subsequent quarters, indicates stagnant performance amidst rising financial challenges. Additionally, the reliance on adoption of specific clinical guidelines and potential reimbursement risks from third-party payors could hinder the widespread use of its diagnostic solutions, negatively impacting the company's financial stability and operational success.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares